Myovant Presses Forward After Latest Positive Trial; Multiple Catalysts Loom
Myovant achieved positive results from its phase 3 HERO study in which the study met on the primary endpoint and all key secondary endpoints for those with advanced prostate cancer. There were 96.7% of men with advanced prostate cancer patients who had sustained testosterone suppression to castrate levels through 48 weeks. Based on the positive …
News story posted on 2019-12-21T16:20:00.0000000Z
